To detect the pathophysiologic link between osteoprotegerin with myocardial failare in chronic kidney disease (СКD) stages III–V was the aim of his research. Osteoprotegerin was measured using commercially kits in 72 CKD stages III–V patients (40 females and 35 males aged 34–67 years). The patients were examined clinically with estimation of the levels of calcium, phosphorus parathormone. Echocardiography on Aloka-4000 unit was made. Left ventricular geometry was assessed by J.Gottdiener classification. Therapy included the correction of anemia, arterial hypertension and phosphorus-calcium metabolism. Mean age of patients was 48±6 years, mean systolic and diastolic blood pressures were 161±22/81±11 mm Hg. Osteoprotegerin high level correlated with renal function and severity of left ventricular hypertrophy. We have shown that the changes of mediator of mineral-bone metabolism osteoprotegerin induced by CKD are independently associated with cardiovascular disfunction.
The aim of our study was to investigate the association of fibroblast growth factor 23 (FGF-23) with сardiorenal outcomes in chronic kidney disease stages III-V. FGF-23 was measured using commercially kits in 83 CKD stages III-V patients (40 females and 43 males aged 37-68 years). The patients were examined clinically with estimation of the levels of parathormone, calcium, phosphorus. Echocardiography on Aloka-4000 unit was made. Left ventricular geometry was assessed by J.Gottdiener classification. Therapeutic policy aimed of correction of anemia, arterial hypertension and phosphorus-calcium metabolism. FGF-23 correlated with renal function and weight of left ventricular hypertrophy. We have shown that changes in bone mediator and phosphate metabolism induced by CKD are independently associated with сardiorenal dysfunction.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.